Research momentum faces demand test; Street targets 15%+ upside
CRISIL reports Q2 on Oct 23 with consensus expectations of continued revenue growth and margin resilience. The Street watches whether Research can sustain its 28% growth run and if FII outflows slow.
The Setup: Research Momentum on Test
CRISIL delivered a broad-based beat in Q1 FY27, with consolidated revenue jumping 27.6% YoY to ₹1,075.39 crore and net profit climbing 26.2% to ₹216.46 crore. The Research arm was the standout, firing on 28% growth. Ahead of Q2 results on October 23, the Street is watching whether this momentum sticks — specifically whether Research can sustain double-digit growth and whether Ratings India, post-merger restructuring (Canada + PriceMetrix consolidated in August), is tracking the full-year guide.
~₹1,070–1,100 Cr
On-plan trajectory; base Q1 ₹1,075 Cr + normal Q2 seasonality
~₹210–225 Cr
Margin resilience test; Q1 PAT ₹216 Cr, guided for low-20% growth
High-20s%
Street watches if 28% Q1 run sustains or normalizes toward guidance
₹10–12/share
H1 already paid ₹10; second interim dividend likely on Oct 23; track full-year payout ratio
What Beats Look Like
A strong quarter: Research revenue remains above 25% growth; Ratings India stabilizes post-merger with revenue ≥15% growth; PAT sustains 25%+ YoY; margins hold above 200 bps of prior-year. Payout stays consistent with H1 run-rate (₹10+ interim). A weak quarter: Research growth dips below 20%; Ratings India post-merger integration drags and shows single-digit growth; PAT growth slows toward low teens; margin compression >100 bps YoY. Dividend guidance is revised downward or payout falls below H1 run-rate.
On Track to Guidance?
CRISIL did not provide explicit FY27 revenue or profit guidance in recent filings, so the "track" is inferred from trajectory: Q1 printed 27.6% revenue growth with PAT up 26.2%. For Q2 to remain on a path toward consistent mid-to-high 20s growth, Research must not falter, and Ratings India must emerge from the Canada merger digestion showing stable mid-high teens growth. The margin narrative is steady: at ₹216 Cr PAT on ₹1,075 Cr revenue, net margin sits ~20%, in line with recent runs. If Q2 mirrors Q1 roughly (allowing for typical quarterly chop), the Street will hold its moderate-growth view; a significant miss would signal guidance headwind.
What the Street Says
Since Last Quarter: Filings & Corp Actions
Jul 21
Revenue ₹1,075 Cr (+27.6% YoY), PAT ₹216 Cr (+26.2%). Second interim dividend of ₹10/share declared; record date Jul 27.
Q1 FY27 Results & Dividend
Jul 21
Routine regulatory update to fair-disclosure policy (SEBI Reg 8(2)).
Insider Trading Code Amendment
Aug 5
Step-down subsidiaries Crisil Canada Inc. & Crisil PriceMetrix Inc. amalgamated; integration underway.
Canada + PriceMetrix Merger Closed
Oct 1
Oct 23 board meeting for Q2 results approval, dividend decision, and any other business.
Board Meeting Intimation
The merger was routine internal restructuring — no material business impact flagged. More significant is the FII outflow: promoter holding steady at 66.64%, but FII ownership slipped from 7.18% in Q4 FY26 to 6.38% in Q1 FY27 (down 80 bps). If Q2 data shows further FII selling, it could signal valuation concerns despite Kotak's upgrade. No pledges or insider dealings reported since Q1.
1 · Research Revenue Growth
Q1's 28% growth was exceptional. Street expects high-20s or sustained 25%+ in Q2. A slip below 20% would signal demand softening and pressure guidance assumptions.
2 · Ratings India Post-Merger Health
August's Canada merger closes a chapter. Look for visibility on Ratings revenue growth (historical mid-teens guidance) and any integration costs. Stable guidance = confidence; revision = caution.
3 · Margin Trajectory & Payout
Net margin has held steady ~20% (PAT ÷ revenue). Q2 will test if this is structural or Q1 was elevated. Also: second interim dividend announcement — sustaining ₹10+/share signals confidence; a cut would flag FCF pressure.
4 · FY27 Guidance & FII View
Management rarely guides explicitly, but Q1/Q2 trends will hint at full-year path. FII outflows (80 bps down) suggest some unease; a bullish commentary could arrest that. Monitor for any commentary on valuation or growth headwinds.
CRISIL enters Q2 riding Q1's strong momentum — 27.6% revenue growth, 26.2% PAT growth, and a research arm in overdrive. The Street has moved from "reduce" (Kotak, July) to "add," and the consensus ₹4,958 target reflects 8.9% upside. But the thesis is narrow: Research has to sustain 25%+ growth, Ratings India has to show it digested the Canada merger without slipping, and margins have to hold. Ownership data flag a caution — FII holdings down 80 bps quarter-on-quarter suggest the Street is cautious on valuation, despite the upgrade. On October 23, focus on Research growth trajectory, post-merger Ratings India revenue, and payout signaling. Earn it, and the 15%+ upside is within reach.
CRISIL Q2 FY27: Consolidated PAT +6% YoY as margins compress despite 20% revenue growth
PAT +6% YoY · revenue +20.2% · margins compressing · miss vs street
₹1,095.16 Cr
+20.2% YoY
₹204.64 Cr
+6% YoY
18.26%
-2.1pp YoY
₹27.97
CRISIL's consolidated PAT for Q2 FY27 (quarter ended 30 September 2026) came in at ₹204.64 Cr, up just 6.0% YoY from ₹193.10 Cr and down 5.5% QoQ from ₹216.46 Cr — a sharp divergence from revenue, which grew 20.2% YoY to ₹1,095.16 Cr (+1.8% QoQ). There are no exceptional items on either side of the comparison, so the YoY PAT growth is effectively as-reported and still only a fraction of the topline gain. Against our pre-result preview (revenue ₹1,070–1,100 Cr, PAT ₹210–225 Cr), revenue landed in-range but PAT missed the low end of the range, making this a street miss on earnings despite an inline top line.
Q2 FY-2027 vs prior quarters
The gap is a margin story. Consolidated NPM fell to 18.26% from 20.36% a year ago (19.74% last quarter) and OPM slipped to roughly 27.5% from 28.9% YoY. Segment data pins the compression on Research, Analytics & Solutions: its revenue grew only 16.5% YoY to ₹749.89 Cr — well short of the "high-20s%" pace the Street was watching for pre-result, and actually down 2.7% sequentially — while its segment margin fell to 17.25% from 21.9% a year ago and 20.4% last quarter. Ratings services was the opposite story: revenue grew 28.9% YoY to ₹345.63 Cr and segment profit rose 28.6% YoY to ₹155.19 Cr, holding a steady ~45% margin, confirming the post-merger integration of Bridge to India has not dented ratings economics. Cost lines outpaced revenue broadly: employee costs +20.3% YoY, professional fees +47.7% YoY, and D&A +38.3% YoY (the latter partly reflecting the Crisil Canada–Pricemetrix amalgamation completed 1 August 2026); other income also fell 30.4% YoY to ₹25.75 Cr, adding a further drag on consolidated PAT versus the operating story.
The stock went into the print at ₹4,750.1, up 5.1% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management issued no formal guidance or outlook commentary in this release (no press release text was available in the context, and none appears in our prior records), so there is no guidance line to grade the print against beyond Street consensus. The Board declared a third interim dividend of ₹17/share, well above the ₹10–12/share our preview had flagged, a signal of confidence that sits somewhat at odds with the margin softness. Standalone PAT was ₹151.94 Cr, up 10.6% YoY from ₹137.39 Cr, aided by ₹85 Cr of dividend income from subsidiaries booked in other income — standalone and consolidated tell different growth stories (10.6% vs 6.0% PAT growth) because the standalone number captures upstreamed dividends rather than the Research segment's operating drag, so neither figure should be read in isolation.
W1
Research, Analytics & Solutions segment margin (17.25% this quarter vs 21.9% a year ago) — whether it stabilises or compresses further next quarter
W2
Research segment revenue growth, which decelerated to 16.5% YoY from the high-20s% pace the Street was tracking pre-result
W3
D&A run-rate (+38.3% YoY to ₹44.18 Cr), partly tied to the Crisil Canada-Pricemetrix amalgamation completed 1 August 2026 — watch for normalisation
Clean digital table, columns unambiguous (30-Sep-26 vs 30-Jun-26 vs 30-Sep-25 verified against context). Sub-cr rounding drift (~₹0.1 Cr) between stated PBT/PAT and recomputed totals is normal filing rounding, not an error. No exceptional items or minority interest line. Standalone other income includes ₹85 Cr dividend from subsidiaries (note 3). Two subsidiaries reviewed by component auditors per the review report, not a numbers flag.